HNF1A and neoplasm: In the unstratified rPDAC cohort, the tumor subtype had statistically non-significant implications for the patients’ prognosis, with KRT81 positivity conferring the worst, double negative an intermediate and HNF1A positivity the best outcome (OS 17.1 vs. 19.3 vs. 22.3 months, p = 0.34, HR 0.87, 95% CI 0.81–0.94; DFS 9.7 vs. 12.1 vs. 12.4 months, p = 0.47, HR 1.08, 95%CI: 0.90–1.28, Supplementary Figure S3A,B), which turned out to be an independent prognostic marker for OS in multivariate analyses (Supplementary Table S10).